Literature DB >> 23833303

BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

Victoria J Mar1, Stephen Q Wong, Jason Li, Richard A Scolyer, Catriona McLean, Anthony T Papenfuss, Richard W Tothill, Hojabr Kakavand, Graham J Mann, John F Thompson, Andreas Behren, Jonathan S Cebon, Rory Wolfe, John W Kelly, Alexander Dobrovic, Grant A McArthur.   

Abstract

PURPOSE: The mutation load in melanoma is generally high compared with other tumor types due to extensive UV damage. Translation of exome sequencing data into clinically relevant information is therefore challenging. This study sought to characterize mutations identified in primary cutaneous melanomas and correlate these with clinicopathologic features. EXPERIMENTAL
DESIGN: DNA was extracted from 34 fresh-frozen primary cutaneous melanomas and matched peripheral blood. Tumor histopathology was reviewed by two dermatopathologists. Exome sequencing was conducted and mutation rates were correlated with age, sex, tumor site, and histopathologic variables. Differences in mutations between categories of solar elastosis, pigmentation, and BRAF/NRAS mutational status were investigated.
RESULTS: The average mutation rate was 12 per megabase, similar to published results in metastases. The average mutation rate in severely sun damaged (SSD) skin was 21 per Mb compared with 3.8 per Mb in non-SSD skin (P=0.001). BRAF/NRAS wild-type (WT) tumors had a higher average mutation rate compared with BRAF/NRAS-mutant tumors (27 vs. 5.6 mutations per Mb; P=0.0001). Tandem CC>TT/GG>AA mutations comprised 70% of all dinucleotide substitutions and were more common in tumors arising in SSD skin (P=0.0008) and in BRAF/NRAS WT tumors (P=0.0007). Targetable and potentially targetable mutations in WT tumors, including NF1, KIT, and NOTCH1, were spread over various signaling pathways.
CONCLUSION: Melanomas arising in SSD skin have higher mutation loads and contain a spectrum of molecular subtypes compared with BRAF- and NRAS-mutant tumors indicating multigene screening approaches and combination therapies may be required for management of these patients. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23833303     DOI: 10.1158/1078-0432.CCR-13-0398

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

Review 2.  Biology and treatment of BRAF mutant metastatic melanoma.

Authors:  Benjamin Y Kong; Matteo S Carlino; Alexander M Menzies
Journal:  Melanoma Manag       Date:  2016-02-12

Review 3.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

Review 4.  The NF1 gene in tumor syndromes and melanoma.

Authors:  Maija Kiuru; Klaus J Busam
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

5.  Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Authors:  Brian D Cholewa; Mary A Ndiaye; Wei Huang; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Lett       Date:  2016-10-25       Impact factor: 8.679

Review 6.  Targeted therapies in melanoma.

Authors:  Stergios J Moschos; Ramya Pinnamaneni
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

7.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

8.  Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.

Authors:  Yuanyuan Li; David M Umbach; Leping Li
Journal:  Melanoma Res       Date:  2017-12       Impact factor: 3.599

Review 9.  Pathways and therapeutic targets in melanoma.

Authors:  Emma Shtivelman; Michael Q A Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T Flaherty; David E Fisher
Journal:  Oncotarget       Date:  2014-04-15

10.  Pump-probe imaging of pigmented cutaneous melanoma primary lesions gives insight into metastatic potential.

Authors:  Francisco E Robles; Sanghamitra Deb; Jesse W Wilson; Christina S Gainey; M Angelica Selim; Paul J Mosca; Douglas S Tyler; Martin C Fischer; Warren S Warren
Journal:  Biomed Opt Express       Date:  2015-08-27       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.